|
End-of-day quote
Bucharest S.E.
10/11/2026
|
5-day change | 1st Jan Change | ||
| 0.2380 RON | -4.80% |
|
-6.30% | +32.22% |
| 08-31 | S.C. Ropharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 05-29 | S.C. Ropharma S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Company Valuation: S.C. Ropharma S.A.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 117.2 | 106 | 95.61 | 102.3 | 82.31 | 92.03 |
| Change | - | -9.57% | -9.83% | 6.95% | -19.5% | 11.8% |
| Enterprise Value (EV) 1 | 248.6 | 232.2 | 228.5 | 249.8 | 224.8 | 203.1 |
| Change | - | -6.6% | -1.59% | 9.35% | -10% | -9.67% |
| P/E | 17.4x | - | 10.4x | 13.2x | -47.7x | 45x |
| PBR | 0.59x | - | 0.41x | 0.43x | 0.34x | 0.36x |
| PEG | - | - | - | -0.8x | 0x | -0x |
| Capitalization / Revenue | 0.15x | 0.12x | 0.1x | 0.09x | 0.06x | 0.06x |
| EV / Revenue | 0.31x | 0.26x | 0.23x | 0.22x | 0.17x | 0.13x |
| EV / EBITDA | 9.92x | 7.4x | 9.45x | 6.9x | 5.46x | 4.58x |
| EV / EBIT | 23.6x | 13.6x | 24.7x | 12.5x | 9.21x | 7.84x |
| EV / FCF | -33.7x | -65.2x | 22.1x | 15.8x | 26.6x | 3.94x |
| FCF Yield | -2.96% | -1.53% | 4.53% | 6.31% | 3.76% | 25.4% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 0.0132 | - | 0.018 | 0.0151 | -0.003375 | 0.004 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 805.9 | 888.2 | 1,002 | 1,120 | 1,323 | 1,538 |
| EBITDA 1 | 25.06 | 31.36 | 24.18 | 36.2 | 41.19 | 44.38 |
| EBIT 1 | 10.55 | 17.11 | 9.256 | 20.02 | 24.42 | 25.89 |
| Net income 1 | 6.753 | 10.73 | 9.216 | 7.718 | -1.726 | 2.181 |
| Net Debt 1 | 131.3 | 126.1 | 132.9 | 147.6 | 142.5 | 111.1 |
| Reference price 2 | 0.2300 | 0.2080 | 0.1870 | 0.2000 | 0.1610 | 0.1800 |
| Nbr of stocks (in thousands) | 509,742 | 509,736 | 511,267 | 511,267 | 511,267 | 511,267 |
| Announcement Date | 28/04/21 | 28/04/22 | 27/04/23 | 25/04/24 | 05/05/25 | 28/04/26 |
1RON in Million2RON
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 25.38M | ||
| 19.45x | 0.86x | 12.87x | -.--% | 17.42B | ||
| 23.43x | 0.41x | 6.26x | 1.93% | 7.14B | ||
| 17.88x | 0.81x | 8.39x | 2.1% | 6.79B | ||
| 21.1x | 0.79x | 13.68x | 1.18% | 6.29B | ||
| 17.17x | 0.76x | 8.14x | 2.36% | 4.55B | ||
| 15.73x | 0.97x | 6.95x | 2.86% | 4.45B | ||
| 15.55x | 0.66x | 5.55x | 4.62% | 3.46B | ||
| 17.86x | 0.38x | 5.89x | 1.29% | 3.19B | ||
| 15.67x | 0.45x | 7.48x | 1.35% | 3.15B | ||
| Average | 18.20x | 0.68x | 8.36x | 1.96% | 6B | |
| Weighted average by Cap. | 18.93x | 0.73x | 9.60x | 1.47% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- RPH Stock
- Valuation S.C. Ropharma S.A.
Select your edition
All financial news and data tailored to specific country editions
















